Gf Fund Management Co., Ltd. - CSI Hong Kong Brand Name Drug Index ETF (SHA:513120)

Assets	n/a
Expense Ratio	0.60%
PE Ratio	18.67
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	-8.68%

Volume	4,695,072,727
Open	1.366
Previous Close	1.357
Day's Range	1.355 - 1.382
52-Week Low	0.958
52-Week High	1.569
Beta	0.65
Holdings	44
Inception Date	Jul 1, 2022

About 513120

513120.SS was created on 2022-07-01 by GF Fund. The fund's investment portfolio concentrates primarily on health care equity. Tightly track the target index, pursue the minimization of tracking deviation and tracking error. The fund strives to control the absolute value of the daily average tracking deviation between the net value growth rate of the investment portfolio & the performance benchmark is less than 0.2%, & the annualized tracking deviation is less than 0.2%.

• Asset Class: Equity
• Category: Health Care
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 513120
• Provider: GF Fund
• Index Tracked: CSI Hong Kong Innovative Drug Index - CNY - Benchmark TR Gross

Performance

513120 had a total return of -8.68% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.54%.

Top 10 Holdings

70.17% of assets

Name	Symbol	Weight
Innovent Biologics, Inc.	1801	10.15%
BeOne Medicines AG	6160	9.76%
WuXi AppTec Co., Ltd.	2359	8.60%
WuXi Biologics (Cayman) Inc.	2269	8.51%
Akeso, Inc.	9926	7.34%
CSPC Pharmaceutical Group Limited	1093	6.36%
Hansoh Pharmaceutical Group Company Limited	3692	6.10%
Sino Biopharmaceutical Limited	1177	5.59%
Cash	n/a	3.89%
3SBio Inc.	1530	3.86%

Data Sources: S&P Global Market Intelligence and Finnhub

Historical data is provided by S&P Global Market Intelligence. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error